DE2128462C2 - Arzneimittel auf Basis von Vitamin-A-Säure-Isomeren - Google Patents
Arzneimittel auf Basis von Vitamin-A-Säure-IsomerenInfo
- Publication number
- DE2128462C2 DE2128462C2 DE2128462A DE2128462A DE2128462C2 DE 2128462 C2 DE2128462 C2 DE 2128462C2 DE 2128462 A DE2128462 A DE 2128462A DE 2128462 A DE2128462 A DE 2128462A DE 2128462 C2 DE2128462 C2 DE 2128462C2
- Authority
- DE
- Germany
- Prior art keywords
- vitamin
- acid
- preparations
- cis
- topical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940079593 drug Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 title description 2
- 150000004508 retinoic acid derivatives Chemical class 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 229960005280 isotretinoin Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000009121 systemic therapy Methods 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 208000003154 papilloma Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical class OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020915 Hypervitaminosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salts Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH947470 | 1970-06-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2128462A1 DE2128462A1 (de) | 1971-12-30 |
| DE2128462C2 true DE2128462C2 (de) | 1982-12-02 |
Family
ID=4352371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2128462A Expired DE2128462C2 (de) | 1970-06-23 | 1971-06-08 | Arzneimittel auf Basis von Vitamin-A-Säure-Isomeren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4464394A (OSRAM) |
| CA (1) | CA967484A (OSRAM) |
| DE (1) | DE2128462C2 (OSRAM) |
| FR (1) | FR2100815B1 (OSRAM) |
| GB (1) | GB1335867A (OSRAM) |
| IE (1) | IE35391B1 (OSRAM) |
| IL (1) | IL37026A (OSRAM) |
| NL (1) | NL170921C (OSRAM) |
| ZA (1) | ZA713539B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2843901A1 (de) * | 1978-10-07 | 1980-04-24 | Basf Ag | Mittel, enthaltend all-e- oder 13-z-7, 8-dehydro-retinsaeure |
| US4877805A (en) * | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
| US4487782A (en) * | 1982-03-26 | 1984-12-11 | Ortho Pharmaceutical Corporation | Topical treatment of non-inflammatory acne |
| US4539154A (en) * | 1983-06-15 | 1985-09-03 | Hoffmann-La Roche Inc. | Polyene compounds |
| CA1282326C (en) * | 1984-12-14 | 1991-04-02 | Paul J. Jarosz | Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient |
| US4545977A (en) * | 1985-01-11 | 1985-10-08 | G. D. Searle & Co. | Compositions and methods for treating severe acne with isotretinoin |
| US4843096A (en) * | 1985-06-26 | 1989-06-27 | Stiefel Laboratories, Inc. | Treatment of acne |
| JP2606711B2 (ja) * | 1986-07-16 | 1997-05-07 | エム． クリグマン，アルバート | 日光で損傷されたヒトの皮膚のレチノイドによる治療方法 |
| DE3853427T2 (de) * | 1987-04-06 | 1995-12-14 | Daltex Medical Sciences Inc | Behandlung gealterter haut mit oraler 13-cis-retinsäure. |
| US5075340A (en) * | 1989-05-22 | 1991-12-24 | Iowa State University Research Foundation | Retinoic acid glucuronide preparations for application to the skin |
| KR100274101B1 (ko) * | 1992-01-22 | 2000-12-15 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 9-시스 레틴산을 함유하는 약제학적 조성물 |
| CZ282548B6 (cs) * | 1992-01-22 | 1997-08-13 | F. Hoffmann-La Roche Ag | Farmaceutický přípravek |
| ES2221921T3 (es) * | 1992-07-13 | 2005-01-16 | Shiseido Company, Ltd. | Composicion para preparacion dermatologica. |
| US6310046B1 (en) * | 1995-11-17 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Sequestrin of Plasmodium falciparum |
| US6733779B2 (en) * | 1999-08-26 | 2004-05-11 | L. Dean Parks | Method of treating benign prostatic hyperplasia and other benign prostate conditions |
| FR2807662A1 (fr) * | 2000-04-12 | 2001-10-19 | Cll Pharma | Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications |
| PT1318791E (pt) | 2000-09-22 | 2004-11-30 | Galephar M F | Composicao farmaceutica semi-solida de isotretinoina |
| EP1455730A4 (en) * | 2001-12-06 | 2006-01-18 | Ranbaxy Lab Ltd | NANOTEHOUS ISOTRETINOINE COMPOSITIONS |
| GB0600134D0 (en) * | 2006-01-05 | 2006-02-15 | Vernique Biotech Ltd | Use of epoxidised molecules |
| US9078925B2 (en) | 2012-06-18 | 2015-07-14 | Galephar Pharmaceutical Research, Inc. | Pharmaceutical semi-solid composition of isotretinoin |
| FR3119130A1 (fr) | 2021-01-28 | 2022-07-29 | Psa Automobiles Sa | Véhicule avec une structure de soubassement comprenant un dispositif de protection contre les chocs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB901659A (en) * | 1959-11-25 | 1962-07-25 | Carolina Julia Cornelia Vintge | Ointment for the treatment of acne vulgaris |
| CH433944A (de) * | 1962-12-17 | 1967-04-15 | Hoffmann La Roche | Präparat zur Vitaminierung von Lebens- und Futtermitteln und Verfahren zu dessen Herstellung |
| CA945068A (en) * | 1967-10-25 | 1974-04-09 | Albert M. Kligman | Composition and method of treating acne |
| PH9210A (en) * | 1969-07-04 | 1975-07-03 | W Bollag | Method for the treatment of carsinomas utilizing compositions containing vitamin a acid compounds |
-
1971
- 1971-06-01 ZA ZA713539A patent/ZA713539B/xx unknown
- 1971-06-08 DE DE2128462A patent/DE2128462C2/de not_active Expired
- 1971-06-10 IL IL37026A patent/IL37026A/en unknown
- 1971-06-21 GB GB2894871A patent/GB1335867A/en not_active Expired
- 1971-06-22 NL NLAANVRAGE7108586,A patent/NL170921C/xx not_active IP Right Cessation
- 1971-06-22 IE IE798/71A patent/IE35391B1/xx unknown
- 1971-06-23 FR FR7122860A patent/FR2100815B1/fr not_active Expired
- 1971-06-23 CA CA116,404A patent/CA967484A/en not_active Expired
-
1981
- 1981-07-15 US US06/283,585 patent/US4464394A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NL170921C (nl) | 1983-01-17 |
| IE35391L (en) | 1971-12-23 |
| IL37026A0 (en) | 1971-08-25 |
| IE35391B1 (en) | 1976-02-04 |
| IL37026A (en) | 1976-06-30 |
| NL170921B (nl) | 1982-08-16 |
| DE2128462A1 (de) | 1971-12-30 |
| US4464394A (en) | 1984-08-07 |
| CA967484A (en) | 1975-05-13 |
| ZA713539B (en) | 1972-02-23 |
| NL7108586A (OSRAM) | 1971-12-27 |
| FR2100815A1 (OSRAM) | 1972-03-24 |
| FR2100815B1 (OSRAM) | 1974-09-27 |
| GB1335867A (en) | 1973-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2128462C2 (de) | Arzneimittel auf Basis von Vitamin-A-Säure-Isomeren | |
| DE69821624T2 (de) | 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN | |
| DE69016821T2 (de) | Behandlungsmittel gegen Osteoarthritis. | |
| EP0501205B1 (de) | Antiphlogistisches Mittel | |
| DE2802924A1 (de) | Heilmittel zur behandlung von akne | |
| DE2241742C3 (de) | Verwendung von Hydroxyprolinderivaten bei der äußerlichen Behandlung von Bindegewebserkrankungen | |
| LU84892A1 (fr) | Komposition zur reduktion der sebumsekretion | |
| EP0004680B1 (de) | Nonatetraensäure-Derivat und pharmazeutische Kompositionen | |
| DE69926881T2 (de) | Zubereitungen zur aknebehandlung | |
| DE3784595T2 (de) | Arzneimittel gegen feste tumoren. | |
| DE2817133C2 (OSRAM) | ||
| US4007268A (en) | Process for alleviating proliferative skin diseases | |
| AT396588B (de) | Verfahren zur herstellung von therapeutisch wirksamen ethern polycyclischer verbindungen | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
| DE69018570T2 (de) | Wasserlösliche Vitamin A-Zubereitungen und deren Verwendung bei der Hautbehandlung. | |
| DE3134709A1 (de) | Antineoplastisch wirkende titanverbindung und diese enthaltende arzneimittel | |
| EP0996438B1 (de) | Verwendung von estern der cis-6-hexadecensäure zur behandlung von psoriasis, allergien und autoimmunerkrankungen sowie bei trockener und empfindlicher haut | |
| DE2803592A1 (de) | Therapeutisches mittel | |
| EP0207421B1 (de) | Verwendung eines Retinoids zur Herstellung eines antikeratinisierenden Arzneimittels | |
| DE2533140B2 (de) | Verwendung von D-Glucuronsäure bzw. deren γ -Lacton | |
| DE69906091T2 (de) | Verwendung von lithium-gluconat zur herstellung eines arzneimittels zur behandlung von herpes und seborrhoischer dermatitis | |
| DE3333008C2 (OSRAM) | ||
| DE2530941C2 (de) | Verfahren zur Gewinnung von kristallinem Aescin und zur Herstellung von bestimmten Aescin-Salzen sowie Triethanolammoniumaescinat und dieses Salz enthaltende Arzneimittel | |
| DE69922398T2 (de) | Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren | |
| DE2843884A1 (de) | Mittel, enthaltend 2-(retinyliden)- malonsaeurederivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination |